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Ability To Develop Broadly Neutralizing HIV-1 Antibodies Is
Not Restricted by the Germline Ig Gene Repertoire
Cathrine Scheepers,*,† Ram K. Shrestha,‡ Bronwen E. Lambson,*,†
Katherine J. L. Jackson,x,{ Imogen A. Wright,‡ Dshanta Naicker,* Mark Goosen,*
Leigh Berrie,* Arshad Ismail,* Nigel Garrett,‖,# Quarraisha Abdool Karim,‖,**
Salim S. Abdool Karim,‖,** Penny L. Moore,*,†,‖ Simon A. Travers,‡ and
Lynn Morris*,†,‖
The human Ig repertoire is vast, producing billions of unique Abs from a limited number of germline Ig genes. The IgH V region
(IGHV) is central to Ag binding and consists of 48 functional genes. In this study, we analyzed whether HIV-1–infected individuals
who develop broadly neutralizing Abs show a distinctive germline IGHV profile. Using both 454 and Illumina technologies, we
sequenced the IGHV repertoire of 28 HIV-infected South African women from the Centre for the AIDS Programme of Research
in South Africa (CAPRISA) 002 and 004 cohorts, 13 of whom developed broadly neutralizing Abs. Of the 259 IGHV alleles
identified in this study, approximately half were not found in the International Immunogenetics Database (IMGT). This included
85 entirely novel alleles and 38 alleles that matched rearranged sequences in non-IMGT databases. Analysis of the rearranged H
chain V region genes of mAbs isolated from seven of these women, as well as previously isolated broadly neutralizing Abs from
other donors, provided evidence that at least eight novel or non-IMGT alleles contributed to functional Abs. Importantly, we
found that, despite a wide range in the number of IGHV alleles in each individual, including alleles used by known broadly
neutralizing Abs, there were no significant differences in germline IGHV repertoires between individuals who do and do not
develop broadly neutralizing Abs. This study reports novel IGHV repertoires and highlights the importance of a fully compre-
hensive Ig database for germline gene usage prediction. Furthermore, these data suggest a lack of genetic bias in broadly
neutralizing Ab development in HIV-1 infection, with positive implications for HIV vaccine design. The Journal of Immunology,
2015, 194: 4371–4378.
T
he induction of broadly neutralizing Abs (bNAbs) is likely
to be crucial for an efficacious HIV vaccine. Although the
majority of chronically HIV-infected individuals develop
some level of cross-neutralizing activity (1), bNAbs are generally
found in ,20% of HIV-infected individuals (2). The mechanisms
underlying bNAb emergence are largely unknown, but a better
understanding of how these Abs arise in natural infection would
provide a blueprint for a vaccine designed to elicit them. Over the
last few years a large number of potent and broad bNAbs have
been isolated from selected HIV-infected donors. These bNAbs
target conserved epitopes on the HIV envelope, including the
membrane proximal external region (MPER), V2 glycans, V3
glycans, CD4 binding site (CD4bs), and the gp120/gp41 interface
(3, 4). However, most bNAbs have unusual genetic features, in-
cluding high levels of somatic hypermutation (SHM), long CDRH3s
(the complementary determining region 3 on the H chain) (3, 5),
and, for some classes, biases in germline IgH V region (IGHV) gene
usage (3, 5–9).
The VRC01 class of Abs to the CD4bs (including NIH45-46,
12A12, 3BNC117, VRC-PG04, and VRC-CH31 isolated from
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multiple donors) was shown to preferentially use either IGHV1-2*02
or IGHV1-46*02 germline alleles (3, 10, 11). This preference is
thought to be due to the electrostatic and hydrophobic contacts
afforded by conserved residues in framework (FR)1, CDRH2, and
FR3 of this allele (some of these features are conserved in IGHV1-
46*02 and IGHV1-3*01, which are also used by CD4bs Abs) (9,
10). Anti-HIV Abs frequently use IGHV1 genes compared with
non-HIVAbs (5, 6). In particular, IGHV1-69 is used by mAbs that
target V2, the CD4 induced site, and gp41 in HIV infection, as
well as other viral infections, such as influenza (8, 12). The
preference for this particular gene can be attributed to the interac-
tion of hydrophobic residues in the CDRH2 with helical elements
or hydrophobic b-sheets like those found on the hemagglutinin of
influenza and gp41 and gp120 of the HIV envelope (8, 13). The
use of IGHV5-51*01 and IGHV5-51*03, which are underrepre-
sented in mature Abs, also was reported to be favored by anti-V3
HIV Abs (6, 7).
The human germline IGHV repertoire consists of seven IGHV
subgroups, which are described in the International Immunoge-
netics Database (IMGT; www.imgt.org). These IGHV1–7 subgroups
include functional genes, open-reading frames, and pseudogenes
with only functional genes being involved in Ab production (14).
IGHV3 is the largest of the IGHV subgroups, with 21 functional
genes, followed by IGHV1 and IGHV4 (both with 10 functional
genes), and IGHV2, IGHV5, IGHV6, and IGHV7 (with three or
fewer genes) (14). Most of these genes have multiple alleles, in-
cluding functional and nonfunctional alleles that differ by either
a single nucleotide polymorphism (SNP) or by multiple SNPs,
which can be either synonymous or nonsynonymous, or frameshift
mutations caused by indels that contribute diversity to the Ig gene
repertoire. Furthermore, whole IGHV genes were reported to have
been duplicated or deleted from the germline repertoire of some
individuals, resulting in varied gene copy numbers (15, 16). IGHV
genes make up the majority of the H chain V region (VH) of
mature Abs and are central to Ag binding. Differences in germline
IGHV repertoires between different populations were highlighted
recently in an extensive study of the human Ig gene locus (16), in
which African individuals were found to be particularly diverse.
Given the propensity of some HIV mAbs to use restricted IGHV
genes, we examined whether HIV-infected individuals who develop
bNAbs have unique IGHV repertoires compared with individuals
who do not, to determine whether the ability to develop these types
of Abs is genetically restricted.
Materials and Methods
Samples and ethics statement
This study involved 28 adult (.18 y) women of African ancestry (mostly
Zulu speaking) with HIV-1 subtype C infection from the Centre for the
AIDS Programme of Research in South Africa (CAPRISA) 002 (17) and
004 (18) cohorts who were being followed at urban and rural clinics in
KwaZulu-Natal, South Africa. Of the 28 women, 13 developed broadly
neutralizing anti-HIV Abs, 13 did not develop broadly neutralizing Abs
despite chronic HIV infection, and 2 were intermediate neutralizers
(Supplemental Table I). Throughout this article, “BCN” is used to refer to
the HIV-infected women who develop broadly neutralizing Abs, and “non-
BCN” refers to women who did not develop broadly neutralizing Abs.
BCN individuals were defined as those whose sera from 2 y postinfection
were able to neutralize 33–94% (median 56%) of a panel of 18 viruses,
made up of 6 subtype A, 6 subtype B, and 6 subtype C viruses, of which 2
viruses were isolated from the women in the cohort. Non-BCN individuals
neutralized 0–11% of the 18 viruses and had the same viral loads as the
BCN individuals at 6 mo postinfection [to remove viral load biases asso-
ciated with the development of bNAbs (19)].
This study was given ethics clearance from the Human Research Ethics
Committee for Medical Research in Johannesburg, South Africa (clearance
number M111104 for this particular study and M080470 for the CAPRISA
parent study).
DNA extraction
Genomic DNA was extracted from PBMCs from each individual. Prior to
extraction, PBMCs were thawed (at 37˚C) and washed with 10 ml RPMI
1640 with 10% FBS. Genomic DNAwas extracted from the pellet from all
28 individuals using a Promega Wizard Genomic purification kit.
Primer design and amplicon library construction
Alignments were created for each IGHV subgroup using sequences ob-
tained from ENSEMBL (http://www.ensembl.org/index.html) and IMGT
(http://www.imgt.org/). Forward primers (with the exception of IGHV1-F)
were mapped to the intron in leader sequence. The reverse primers were
mapped to the intron after the CDR3 region. IGHV1, IGHV3, and IGHV4
primers were designed based on previously published primer sets (20).
New primers for IGHV2, IGHV5, IGHV6, and IGHV7 were designed
based on related sequences for each subgroup. A total of eight primer sets
was designed to amplify all seven subgroups. The binding properties of the
primer sets were determined using University of California Santa Cruz’s
BLAT database (https://genome.ucsc.edu/cgi-bin/hgBlat?command=start)
and the National Center for Biotechnology Information (NCBI)’s basic
local alignment search tool (BLAST). Additional next-generation se-
quencing (NGS)-specific sequences were added to the gene-specific pri-
mers to allow sequencing of the Roche 454 and Illumina MiSeq. The 454
primers included the 454 adapter sequence, key sequence, and 10-bp MID
sequences (four unique sequences in total; primers are listed in Supplemental
Table II). The Illumina MiSeq primers included a MiSeq index-binding tag
and the read 1 or read 2 tags (used for paired-end reads; primers are listed
in Supplemental Table III). Nextera XT Indexing tags, which allow pooling
of samples on the MiSeq, were added during library construction rather
than included into the primer.
Each IGHV subgroup was amplified three times for each individual to
ensure adequate coverage of the subgroup andminimize PCR bias. The PCR
conditions for all eight amplicons and both 454 and Illumina primers were
the same, with the exception of the annealing temperatures: 56˚C for
IGHV1, IGHV3a, and IGHV5; 59˚C for IGHV2, IGHV6, and IGHV7; and
55˚C for IGHV3b and IGHV4. The PCR conditions were as follows: initial
denaturation at 94˚C for 3 min, 35 cycles of denaturation at 94˚C for 15 s,
annealing for 45 s, extension for 1 min at 72˚C, final extension at 72˚C for
8 min, and held at 4˚C. Each PCR contained 17.5 ml dH2O, 2.5 ml Roche
FastStart High Fidelity 103 buffer with 18 mM MgCl2, 0.5 ml deoxyri-
bonucleotide triphosphates mix (10 mM each), 1 ml each primer (10 mM),
0.25 ml Roche FastStart High Fidelity Enzyme (5 U/ml), and 1 ml 10 ng/ml
DNA. The PCR amplicon lengths ranged from ∼390 to 440 bp. All rep-
licates of the eight amplicons from each individual were pooled to create
a full IGHV repertoire for each individual.
Next-generation sequencing
Fifteen individuals were sequenced on the Roche 454 GS Junior, with four
individuals pooled per sequencing run. All clean-up procedures and se-
quencing on the Roche 454 GS Junior (Titanium) was done as per the
manufacturer’s recommendations.
To confirm rare alleles that were only found in single individuals, 11 of
the individuals sequenced on the GS Junior were resequenced on the
Illumina MiSeq along with 13 additional individuals. A custom amplicon-
sequencing approach was used for the MiSeq sequencing. Nextera XT
Indexing tags were added to the pooled MiSeq amplicon libraries for each
individual using 5 ml each Nextera XT index (two per sample), 1 ml
cleaned PCR product (amplicon library prep), 0.5 ml Epicentre FailSafe
enzyme, 25 ml Epicentre FailSafe PCR PreMix, and 13.5 ml dH2O.
Thermocycler conditions were 72˚C for 3 min, 95˚C for 30 s, 12 cycles of
95˚C for 10 s, 55˚C for 30 s, and 72˚C for 30 s, followed by a final ex-
tension at 72˚C for 5 min. All products were checked on an Agilent
Bioanalyzer and cleaned up using 0.753 AMPure Beads, according to the
manufacturer’s protocol. Each sample was quantified on a Qubit and di-
luted to 8 nM. A single 8-nM pooled library was created by pooling 4 ml
each diluted sample, 5 ml of which was denatured using 5 ml 0.2 N NaOH,
according to the MiSeq protocol. A final concentration of 12 pM denatured
DNA library with 15% PhiX control was run onto the Illumina MiSeq,
using the MiSeq reagent kit (version 2) with 2 3 250 paired-end reads.
Sequence data analysis
FASTQ files were extracted from the raw GS Junior output (.sff files) or
automatically generated on the MiSeq. The resulting sequences were quality
trimmed using QTrim (21). Sequences with a minimum read length of 260 bp
and a mean quality score $ 23 ($ 99% confidence) were considered high
quality and used for downstream analyses. Paired-end MiSeq reads were
merged using PEAR (22), after quality trimming. All identical sequences
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were collapsed to single unique reads. Unique reads compiled from six or
more identical sequences were used for further analysis, whereas all unique
reads compiled from less than six sequences were discarded from further
analysis. The unique sequences were compared with a database of IGHV
alleles downloaded from IMGT using a custom BLAST approach with
a match reward score of 2, a mismatch penalty of 5, a gap penalty for
insertions of 16, and a gap extension for deletions with a penalty of 4. All
related sequences for each IGHV gene were aligned using RAMICS (23).
Sequences with 100%matches to functional IMGTalleles were assigned
as that particular IMGT allele. Sequences matching open-reading frames
or pseudogenes were removed from further analysis. Sequences with non-
synonymous and/or synonymous SNPs, insertions, or deletions compared with
their top matched functional IMGT sequence were given the name of the top-
scoring IMGT match with the suffix “m” to denote a single mismatch
(nonsynonymous and synonymous SNPs) (e.g., IGHV1-2*5m) and “mm” for
multiple SNPs, insertions, or deletions (e.g., IGHV1-2*5mm). If more than
one sequence with a single mismatch or multiple mismatches to the same top-
scoring IMGT functional sequence was observed, an additional numerical
identifier was given to the name (e.g., IGHV1-2*5m2 and IGHV1-2*5mm2).
These sequences were compared with those listed in the Ig Polymorphism
Database, GenBank, NCBI’s dbSNP, NCBI’s IgBLAST, and other published
IGHV data (24–28). If 100% matches were found in any of these databases or
publications, these sequences are described as non-IMGT alleles. If no match
was found, and sequences were observed in multiple individuals or in both
sequencing platforms in a single individual, we report these as novel alleles.
bNAb sequences were obtained from the HIV Sequence Database -
CATNAP (http://www.hiv.lanl.gov/components/sequence/HIV/neutralization/
main.comp) or GenBank. The germline IGHV gene usage for these se-
quences also was obtained from CATNAP or the relevant publication. The
bNAb sequences were compared with our IMGT, non-IMGT, and novel
allele sequences, using blastn from BLAST 2.2.29+ with a match reward
of 1, a mismatch penalty of 21, gap deletions of 5, a gap extension of 2,
a word size of 7, and an E value threshold of 1e210. mAbs were isolated
previously from seven of the CAPRISA participants examined in this study
using single-cell sorting and PCR amplification of the H and L chains
(N. Mkhize, E. Gray, and L. Morris, unpublished observations). The majority
of these mAbs were not HIV specific. The sequences obtained from these
mAbs were used to assign germline IGHV gene usage in each participant.
Statistical analysis
The two-tailed Fishers exact test with 95% confidence intervals was used to
assess the difference in germline gene repertoires between the BCN and
non-BCN sample groups.
Results
Novel germline IGHV alleles in South African women
The germline IGHV gene repertoire of 28 HIV-infected women in
the CAPRISA 002 and 004 cohorts, based in KwaZulu-Natal, South
Africa, were sequenced using both the 454 and Illumina NGS
platforms. Sequences with perfect matches to alleles listed in
IMGT (29) were given the IMGTallele name and are referred to as
FIGURE 1. Novel germline IGHValleles in 28 South African individuals. (A) Number of alleles observed for each IGHV gene. Shown are the numbers
of novel (red), non-IMGT (orange), and IMGT (blue) alleles. (B) Prevalence of novel and non-IMGT germline IGHV alleles. (C) Number of non-
synonymous changes in each allele compared with top-matched IMGT allele. (D) Number of synonymous changes in each allele compared with top-
matched IMGT allele. (E) Total number of IMGT, novel, and non-IMGT germline IGHV alleles. BCN individuals are highlighted in black, and non-BCN
individuals are highlighted in gray. (F) Total number of germline alleles from each IGHV subgroup. Shown are the total numbers of alleles colored
according to IGHV subgroup.
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IMGT alleles. Sequences that did not match IMGT alleles as
a result of synonymous or nonsynonymous mutations or indels,
but were matches to non-IMGT Ig gene databases (30–33) or Ig
gene publications (24–28), were given the published name and are
referred to as non-IMGT alleles. Sequences with no matches to
either IMGT or non-IMGT alleles and were observed in multiple
individuals or across both technologies in one individual are re-
ferred to as “novel” alleles.
A total of 47 functional IGHV genes representing all seven
subgroups was found in our cohort (Fig. 1A). Only one published
gene, IGHV3-NL1, first identified in Papua New Guinea (20), was
not detected. There was a wide range in the number of alleles
associated with each gene, with 20 alleles in the IGHV2-70 gene
compared with only a single allele for the IGHV3-20 gene. Of the
259 alleles identified in this population, just over half (∼52%, n =
136) had an exact match to those listed in IMGT, whereas ∼15%
(n = 38) were non-IMGT alleles, and ∼33% (n = 85) were novel
alleles. Eighty-one of the eighty-five novel alleles (95%) were
observed in more than one individual (Fig. 1B). The four novel
alleles observed in single individuals were confirmed with both
454 and Illumina sequences. The most commonly observed novel
alleles were IGHV6-1*1m1 found in 25 individuals (∼89%) and
IGHV2-26*1m2 found in 20 individuals (∼71%), both of which
contained a single SNP compared with the known alleles. Overall,
48% (n = 60) of the novel and non-IMGT alleles identified in this
study were found in at least four individuals, indicating that many
are fairly common. Furthermore, this study significantly expanded
the number of alleles for certain genes. For example, IGHV6-1,
which only had 2 alleles reported in IMGT was found to have 10
novel alleles and 1 non-IMGT allele (Fig. 1A, 1B). Similarly,
IGHV2-26 was found to have 13 alleles (including 10 novel
alleles and 2 non-IMGT alleles) compared with 1 recorded in
IMGT. Other significant expansions were in the IGHV1-69 and
IGHV2-70 genes.
The majority (∼97%, n = 119) of novel and non-IMGT alleles
had single or multiple SNPs (synonymous and nonsynonymous),
FIGURE 2. Phylogenetic tree of all germline IGHValleles observed in 28 South African individuals. Shown are all IMGT, non-IMGT, and novel alleles
observed in this study. Alleles are colored according to IGHV subgroup, and the non-IMGT and novel alleles are highlighted in the gray boxes.
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with single nonsynonymous SNPs being the most common
(Fig. 1C, 1D). One novel allele (IGHV2-26*1mm4, observed in 15
individuals) had eight nonsynonymous SNPs (Fig. 1B, 1C). Four
novel alleles had indels relative to their most closely matched
IMGT allele, and three of the four had additional SNPs. IGHV3-
11*5mm, observed in two individuals, had a full codon insertion,
whereas frameshifts as a result of single nucleotide deletions were
found in IGHV4-59*8mm and IGHV4-61*2mm, each observed in
two individuals, and IGHV6-1*1m8, which was found in six
individuals. It is likely that these three alleles with the frameshift
mutations are not functional, but rather are novel pseudogenes.
When the repertoires for each of the 28 individuals were ana-
lyzed separately, it was apparent that there was a wide range in the
number of alleles/individual (Fig. 1E, 1F). CAP295 had the largest
number of alleles (n 5 105), whereas CAP322 had the fewest
(n5 23). Each individual’s repertoire included IMGT, non-IMGT,
and novel alleles. There was variation in the number of alleles/
IGHV family, because some individuals lacked alleles for IGHV6
or IGHV7, whereas others had smaller numbers of IGHV2,
IGHV4, or IGHV5 alleles. A phylogenetic tree of all 259 alleles,
including IMGT, non-IMGT, and novel alleles, sequenced in this
study revealed separate clustering of each of the IGHV subgroups,
with all of the novel and non-IMGT alleles clustering with their
respective IMGT genes (Fig. 2).
Novel germline IGHV allele usage in bNAbs
To determine whether these novel and non-IMGT germline alleles
are being used by the human immune system to generate functional
Abs, we analyzed the germline gene usage of mAbs isolated from
seven of the CAPRISA participants in this study. We found 15
mAbs that made use of seven novel or non-IMGT alleles identified
from NGS of the 28 individuals (Fig. 3A). Of these, two clonally
related mAbs were HIV-1 specific (CAP255-37C and CAP255-
18F). An example of one of the non-IMGT alleles used by two
mAbs isolated from two individuals (CAP177 and CAP248) is
shown in Fig. 3B. Based on the IGHV repertoires from CAP177
and CAP248, the germline IGHV gene predicted to be used by
these two mAbs is IGHV2-5*9m, which has a serine (S) at po-
sition 62 rather than a glycine (G) present in the closest related
IMGT allele IGHV2-5*09. Compared with the germline allele, all
other SNPs found in these two mAbs are likely the results of
SHM. Of the remaining seven novel and non-IMGT alleles used
by these mAbs, four (57%) had a better match at the amino acid
level and three (43%) had a better match at the nucleotide level
compared with the closest matching IMGT allele (Fig. 3A). We
also analyzed the IGHV gene usage of 57 well-known HIV-1
bNAbs and found 14 instances in which the novel or non-IMGT
alleles, identified in this study, provided the same or a better match
than did their currently predicted IMGT allele (Fig. 3C). Two of
the predicted alleles (IGHV4-39*7m2 and IGHV4-59*1m2) also
were observed among the mAbs isolated from the CAPRISA
participants. An example of alternate IGHV allele usage for the
bNAbs is shown in Fig. 3D: PGT130 and PGT131 are more likely
to be using IGHV4-39*7m1 or IGHV4-39*7mm, which like the
mAbs have a valine (V) at the second amino acid, rather than
a leucine (L), as seen in IGHV4-39*07.
Comparison of germline IGHV repertoires in BCN and
non-BCN individuals
Given that some HIV broadly neutralizing mAbs show biased
variable H chain gene usage, we analyzed the germline IGHV
repertoires of BCN and non-BCN individuals to determine whether
the ability to develop bNAbs was associated with a particular
genotypic profile. Among the 28 CAPRISAwomen, 13 developed
bNAbs in their plasma after 2–4 y of HIV infection; 13 women did
not develop bNAbs, despite matching viral loads; and 2 were in-
termediate neutralizers [Supplemental Table I (19) and N. Mkhize,
E. Gray, and L. Morris, unpublished observations]. Comparison of
the BCN and non-BCN individuals revealed that they had similar
profiles of IGHV genes (Fig. 4A), approximately the same number
of alleles for each of those genes (Fig. 4B), and the same number
of potential alleles (Fig. 1E, 1F). The only gene that showed
FIGURE 3. Novel IGHValleles used by isolated mAbs and some bNAbs. (A) Germline IGHVallele usage for isolated mAbs from study participants. The
germline IGHV alleles used, as well as their corresponding IMGT allele, nucleotide, and amino acid substitutions between the two alleles, are shown. (B)
Alignment of germline IGHV allele usage for isolated mAbs from two study participants. Highlighted in yellow are the differences in amino acids at
position 62: G (glycine) and S (serine). Amino acid changes not highlighted in the figure are likely a result of SHM during Ab maturation. (C) Germline
IGHV allele usage for selected bNAbs. The published IMGT predicted allele and alternate allele(s) predicted from IGHV alleles in 28 South African
individuals are shown. (D) Alignment of predicted germline IGHV allele usage for PGT130 and PGT131. Highlighted in yellow are the differences at the
second amino acid: V (valine) and L (leucine). Amino acid changes not highlighted in the figure are likely a result of SHM during Ab maturation.
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statistical significance between the two groups was IGHV3-30
(p = 0.035, although significance was lost following Bonferroni
multiple testing correction); non-BCN individuals had five more
alleles (n = 11) compared with BCN individuals (n = 6) (Fig. 4B).
We also compared the frequency of the specific germline IGHV
alleles used by broadly neutralizing mAbs between the non-BCN
and BCN groups. Of the 57 monoclonal bNAbs targeting one of
four different epitopes on the HIV envelope glycoprotein, most
made use of IGHV1, IGHV3, and IGHV4 germline genes (Fig. 4C),
and, as reported above, some may use novel/non-IMGT alleles
(Fig. 3C). This included IGHV1-46*02, used by some CD4bs
Abs; however, there were two other alleles for this gene, including
IGHV1-46*01, which were found in all individuals. Similarly,
IGHV3-15*05 (used by bNAb 10E8) and IGHV3-33*05 (used by
bNAbs PG9 and PG16) were not observed in any of the individ-
uals in this study, but other alleles were more commonly observed,
FIGURE 4. Comparison of germline IGHV repertoires between BCN and non-BCN individuals. (A) Number of BCN and non-BCN individuals
with each of the functional IGHV genes in their IGHV repertoire. (B) Number of alleles observed for each of the functional IGHV genes in BCN
and non-BCN individuals. (C) Number of BCN and non-BCN individuals with the same IGHV alleles in their repertoire as those used by
monoclonal bNAbs.
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including some novel/non-IMGT alleles. The IGHV1-2*02 allele,
which is also used preferentially by CD4bs Abs (shown in blue
in Fig. 4C), occurred at high frequency in both the non-BCN and
BCN groups. The most prevalent IGHV alleles in both groups
were IGHV4-59*01 (used by the CD4bs bNAb CH103 and the
V3/glycan bNAbs PGT121–123), IGHV1-2*02 (used by CD4bs
mAbs), IGHV1-3*01 (used by the CD4bs bNAb IgG1b12), and
IGHV2-5*01/05 (used by bNAb 2F5 that targets the MPER).
Importantly, there was no difference in the frequency of any of
these alleles between the 13 BCN and 13 non-BCN individuals.
Thus, the inability of all HIV-infected individuals to develop
bNAbs is not due to a paucity of the relevant alleles in their IGHV
germline gene repertoires.
Discussion
We analyzed the germline IgH variable gene repertoire encoded in
the genomic DNA of individuals from KwaZulu-Natal, South
Africa, and noted that ∼48% of the alleles seen in this population
are not reported in IMGT. Some of these alleles (non-IMGT
alleles) were described in published studies of rearranged Abs,
although most alleles were novel and are described in this article
for the first time, to our knowledge. Further analysis of these
IGHV repertoires revealed there to be no differences between
individuals who developed bNAbs to HIV and those who did not,
despite equivalent antigenic load. Because the induction of these
types of Abs is considered essential for an effective HIV vaccine,
these data suggest that the ability to develop bNAbs is not re-
stricted by the IGHV repertoire.
Previous studies reported differences in the frequencies of IGHV
genes between different populations, with Africans showing par-
ticularly unique profiles (16). The presence of IGHV3-64D,
IGHV5-10-1, and IGHV7-4-1 was reported to be lower in Afri-
can (Luyha, Maasai, and Yoruba) populations compared with
Asian and European groups (16). We found a similarly low fre-
quency of IGHV3-64D (14%) in this Zulu-speaking South African
population. However, IGHV5-10-1 was observed at a higher prev-
alence (64%) compared with the studied African, Asian, and
European groups (0.03–16, 20–21, and 34–48%, respectively) (16),
whereas IGHV7-4-1 frequencies were similar (75%) to those seen
in Asian (∼78%) and European (54–75%) groups (16). IGHV1-69-2,
IGHV3-43D, and IGHV4-38-2 genes were reported to be common
in African populations (16), which we corroborated in our study for
IGHV1-69-2 and IGHV4-38-2 (75 and 61%, respectively). However,
we observed IGHV3-43D*01 in only 29% (8/28) of individuals
studied, which is lower than the prevalence reported in other African
groups (45–65%) (16).
We showed that both novel and non-IMGTalleles are being used
by mAbs isolated from individuals in this study, as well as some
well-characterized anti-HIV bNAbs. This included CH103 and 12
Abs in the PGT121-137 series, all of which were isolated from
African donors (34–36). Given that three of the novel and non-
IMGT alleles (IGHV3-21*1m, IGHV4-39*1m2, and IGHV4-
39*7m2) potentially being used by these bNAbs were fairly
common in the South African individuals (39, 36 and 21%, re-
spectively), it is perhaps not surprising that these were found to
contribute to functional Abs in other African individuals. IGHV4-
39*7m1 and IGHV4-39*7mm were less common in our study
group (4 and 11%, respectively). The other novel and non-IMGT
alleles used by mAbs isolated from the study participants also
were fairly commonly observed, ranging from 14 to 36%. Only 2
of the 15 mAbs isolated from the study participants were able to
bind HIV, highlighting that the use of novel and non-IMGT alleles
by functional Abs is not HIV specific and, thus, could play a role
in immune responses to other diseases or infections.
Despite the wide range in the number of IGHValleles present in
each individual, there were no differences in the overall germline
IGHV repertoires between BCN and non-BCN individuals. This
extended to a subanalysis of the genes and alleles used by known
broadly neutralizing mAbs whose frequency differed within the
cohort but not between BCN and non-BCN groups. The only gene
that showed a difference between the two groups was IGHV3-30:
non-BCN individuals had more alleles than did BCN individuals.
IGHV3-30 is used by the CAP256-VRC26 family of broad and
potent V1V2 Abs, which were isolated from CAPRISA donor
CAP256, a participant in this study (37). We also noted that al-
leles IGHV1-46*02, IGHV3-15*05, and IGHV3-33*05, used by
CD4bs, MPER, and V2 glycan bNAbs, respectively, were not
found in this South African cohort. However, other alleles of these
genes were observed in this cohort, as well as allelic variants used
by other bNAbs targeting the same epitopes. Thus, although the
specific alleles used by these bNAbs were not present, it did not
preclude these individuals from generating Abs to these epitopes.
In addition, CH103 and PGT121-123, which both use IGHV4-
59*01 (or the non-IMGT allele IGHV4-59*1m2), target different
epitopes (CD4bs and V3 glycans, respectively), demonstrating
that a single germline allele can be used by Abs against numerous
HIV envelope targets.
The germline IGHV gene makes the greatest contribution to
the unmutated common ancestor (UCA) Ab encoding the entire
CDRH1, CDRH2, FR1, FR2, and FR3 regions. Elegant studies on
the UCAs of the VRC01 class of Abs, which use the VH1-2*02
allele, showed how two glycans in the V5 region of the HIV en-
velope obstruct binding of the UCA (9, 38). Such studies guide the
design of suitable envelope immunogens able to trigger the
VRC01 class of Abs (9). However, other studies aimed at iden-
tifying UCA-binding envelopes for PG9 and other bNAb lineages
were less successful, primarily because the UCA approximations
used in such studies were predicted from highly mutated Abs and
using incomplete germline databases. The public availability of
a comprehensive database of germline Ig genes, including data
from this study (available from the authors), will significantly
enhance the accuracy with which UCAs can be inferred.
By studying an underrepresented population group in southern
Africa, this investigation has greatly expanded the repertoire of
germline IGHV genes. We further hypothesize that the IGHD and
IGHJ germline genes, which make up the remainder of the VH
region of functional Abs, are also likely to be highly variable
within this population and, thus, warrant investigation. Further-
more, we showed that some of these novel and non-IMGT alleles
are functionally active in both HIVand non-HIVAbs. This knowledge
will contribute to a better understanding of the Ab response to HIV,
as well as other infections, immunizations, and B cell pathologies.
Importantly, we also showed that the development of bNAbs
against HIV is not restricted by the germline IGHV repertoire,
which is significant for vaccine development, because it suggests
that everyone has the potential to make Abs capable of neutralizing
all strains and subtypes of HIV.
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